Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 27, 2021
Distillery Therapeutics

Improving cardiac cell therapy for MI with KCNN4 overexpression

BioCentury | May 24, 2018
Translation in Brief

Channel for T cell invasion

How KCa3.1 channel activation could reverse the migration effects of adenosine signaling
BioCentury | Sep 29, 2017
Financial News

SpringWorks launches with $103M series A

BioCentury | Sep 29, 2017
Finance

Spring cleaning

SpringWorks provides a development path for pharma's de-prioritized assets
BioCentury | Sep 25, 2017
Financial News

SpringWorks launches with $103M series A

BioCentury | May 2, 2017
Financial News

Tetragenetics gets JDRF investment

BioCentury | Jan 21, 2010
Distillery Therapeutics

Indication: Autoimmune disease

BioCentury | Sep 7, 2009
Clinical News

Senicapoc: Preliminary Phase IIa data

BioCentury | Aug 20, 2009
Distillery Therapeutics

Indication: Renal disease

Items per page:
1 - 10 of 18
Help Center
Username
Request a Demo
Request Training
Ask a Question